Artiva Ends AlloNK Development After Risk Benefit Review
Artiva announced on 27 October that it will stop all AlloNK clinical development, abandon a planned Phase III rheumatoid-arthritis study, reduce its workforce by about 94%, and examine strategic alternatives. Longer follow-up did not…
